...
首页> 外文期刊>FEMS immunology and medical microbiology >The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
【24h】

The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.

机译:皮肤炭疽感染患者对炭疽芽孢杆菌毒素的早期体液免疫反应。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Bacillus anthracis, the causative agent of anthrax, produces a tripartite toxin composed of two enzymatically active subunits, lethal factor (LF) and edema factor (EF), which, when associated with a cell-binding component, protective antigen (PA), form lethal toxin and edema toxin, respectively. In this preliminary study, we characterized the toxin-specific antibody responses observed in 17 individuals infected with cutaneous anthrax. The majority of the toxin-specific antibody responses observed following infection were directed against LF, with immunoglobulin G (IgG) detected as early as 4 days after the onset of symptoms in contrast to the later and lower EF- and PA-specific IgG responses. Unlike the case with infection, the predominant toxin-specific antibody response of those immunized with the US anthrax vaccine absorbed and UK anthrax vaccine precipitated licensed anthrax vaccines was directed against PA. We observed that the LF-specific human antibodies were, like anti-PA antibodies, able to neutralize toxin activity, suggesting the possibility that they may contribute to protection. We conclude that an antibody response to LF might be a more sensitive diagnostic marker of anthrax than to PA. The ability of human LF-specific antibodies to neutralize toxin activity supports the possible inclusion of LF in future anthrax vaccines.
机译:炭疽杆菌是炭疽的病原体,它产生由两个酶活性亚基致命因子(LF)和浮肿因子(EF)组成的三方毒素,当与细胞结合成分结合时,形成保护性抗原(PA)致命毒素和浮肿毒素分别。在这项初步研究中,我们表征了在感染了皮肤炭疽的17个人中观察到的毒素特异性抗体反应。感染后观察到的大多数毒素特异性抗体反应都针对LF,最早在症状发作后4天就检测到了免疫球蛋白G(IgG),而后来的EF和PA特异性IgG反应则较低。与感染的情况不同,用吸收的美国炭疽疫苗和沉淀的英国炭疽疫苗免疫的人的主要毒素特异性抗体反应是针对PA的。我们观察到,LF特异性人抗体像抗PA抗体一样,能够中和毒素的活性,表明它们可能有助于保护作用。我们得出结论,对LF的抗体反应可能是对PA的更敏感的炭疽诊断标志。人LF特异性抗体中和毒素活性的能力支持在未来的炭疽疫苗中可能包含LF。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号